Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Gemcitabine, and Capecitabine in CUP
NCT00148135Phase 2
Key facts
- Status
- Terminated
- Start
- May 2001
- Primary completion
- Apr 2006
- Countries
- 1
- Sponsor
- University of Michigan Rogel Cancer Center
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Conditions
- carcinoma of unknown primary (CUP)
01
Overview
Phase 2, open-label trial of carboplatin, gemcitabine and capecitabine in carcinoma of unknown primary (CUP), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Objective Response Rate. Started May 2001; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Patients with histologically confirmed carcinoma of unknown primary (CUP) who are not candidates for specific subset treatment, have measurable disease, and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Overall Survival
Toxicity
1-Year Survival Rate
Beyond the preview
Go deeper on NCT00148135.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148135.